http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 02 Jun 2026 07:30:23 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html <p>Kazia Therapeutics Limited (NASDAQ: KZIA) appointed James Levine as Chief Financial Officer, effective June 1. The clinical-stage oncology company announced the executive change as it advances its cancer therapy pipeline.</p> <p>Levine brings over 20 years of experience in investment banking and executive leadership at publicly traded biotechnology companies. He most recently served as CFO of Cardiff Oncology, a clinical-stage oncology company developing treatments for solid tumors.</p> <p>Prior to Cardiff Oncology, Levine was CFO at Cidara Therapeutics, where he led financial structuring of a $568 million licensing collaboration with Mundipharma and a $780 million global partnership with Janssen Pharmaceuticals. He also served as http://www.streetinsider.com/Management+Changes/Kazia+Therapeutics+names+James+Levine+as+CFO/26587475.html Tue, 02 Jun 2026 07:30:23 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686 http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/au..sydney" idsrc="xmltag.org" >SYDNEY</location></span>, <span class="legendSpanClass"><chron>June 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://www.kaziatherapeutics.com/site/content/" target="_blank" rel="nofollow"><span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics Limited</span></a> (NASDAQ: KZIA) ("Kazia," "<span value="NASDAQ-SMALL:KZIA" idsrc="xmltag.org" >Kazia Therapeutics</span>" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of <person value="APIN:1727239962">James Levine</person> as Chief Financial Officer, effective <chron>June 1, 2026</chron>. <person>Mr. Levine</person> brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.</p> <p>"James has built an impressive career leading financial strategy, strategic transactions and major pharmaceutical collaborations, following http://www.streetinsider.com/Press+Releases/Kazia+Therapeutics+Appoints+James+Levine+as+Chief+Financial+Officer/26587465.html Tue, 02 Jun 2026 07:30:00 -0400 A.03607790 A.08001773 A.10371245 A.21079188 A.21873776 A.22591554 A.50210924 KZA KZIA O.00042037 O.00176505 O.00376292 O.00673961 O.00832301 O.20147506 O.26292164 O.51342686